Oncology
PRO, longitudinal, responder and time-to-event methodology in oncology development contexts.
THERAPEUTIC EXPERIENCE
Therapeutic & Development Experience
Selected team experience across therapeutic contexts where disease course, endpoint strategy and interpretation materially affect the biometrics approach.
THERAPEUTIC CONTEXTS
Selected Therapeutic Experience
Indication-specific relevance is confirmed during scoping based on TUNECT project delivery and the relevant background of the proposed specialists.
Infectious Diseases
Clinical data and statistical-analysis support in anti-infective development contexts.
Inflammatory / Immune-Mediated Conditions
Repeated measures, responder endpoints and complex longitudinal data workflows.
Ophthalmology
Clinical data and biometrics experience in ophthalmic programs.
Cardiology
Experience including arrhythmia and other cardiovascular data contexts.
Endocrinology
Clinical data and statistical support in endocrine-related programs.
DEVELOPMENT CONTEXT
Rare-Disease & Small-Population Studies
Rare-disease programs are a development context rather than a therapeutic area. Small populations can require careful design assumptions, endpoint strategy, missing-data handling and interpretation.
Small Samples
Design and analysis choices need transparent assumptions and a clear link to the estimand and decision need.
Complex Endpoints
Longitudinal, responder and composite endpoint structures may require study-specific sensitivity and interpretation plans.
CONTEXT
Why Therapeutic Context Matters
The analytical workflow changes with the clinical question.
Endpoint Strategy
Endpoint meaning and timing determine the analysis framework.
Missing Data & Intercurrent Events
Disease course and treatment pathways affect assumptions and sensitivity analyses.
Interpretation
Statistical results must remain clinically meaningful and aligned with the objective.
Do you need experience in a specific therapeutic area?
Send us the indication, phase and expected biometrics scope.